 |
|
Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate
A Randomized Controlled Trial
Gregory J. Merten, MD;
W. Patrick Burgess, MD, PhD;
Lee V. Gray, MD;
Jeremiah H. Holleman, MD;
Timothy S. Roush, MD;
Glen J. Kowalchuk, MD;
Robert M. Bersin, MD;
Arl Van Moore, MD;
Charles A. Simonton III, MD;
Robert A. Rittase, PharmD;
H. James Norton, PhD;
Thomas P. Kennedy, MD, MPH
JAMA. 2004;291:2328-2334.
ABSTRACT
| |
Context Contrast-induced nephropathy remains a common complication of radiographic procedures. Pretreatment with sodium bicarbonate is more protective than sodium chloride in animal models of acute ischemic renal failure. Acute renal failure from both ischemia and contrast are postulated to occur from free-radical injury. However, no studies in humans or animals have evaluated the efficacy of sodium bicarbonate for prophylaxis against contrast-induced nephropathy.
Objective To examine the efficacy of sodium bicarbonate compared with sodium chloride for preventive hydration before and after radiographic contrast.
Design, Setting, and Patients A prospective, single-center, randomized trial conducted from September 16, 2002, to June 17, 2003, of 119 patients with stable serum creatinine levels of at least 1.1 mg/dL ( 97.2 µmol/L) who were randomized to receive a 154-mEq/L infusion of either sodium chloride (n = 59) or sodium bicarbonate (n = 60) before and after iopamidol administration (370 mg iodine/mL). Serum creatinine levels were measured at baseline and 1 and 2 days after contrast.
Interventions Patients received 154 mEq/L of either sodium chloride or sodium bicarbonate, as a bolus of 3 mL/kg per hour for 1 hour before iopamidol contrast, followed by an infusion of 1 mL/kg per hour for 6 hours after the procedure.
Main Outcome Measure Contrast-induced nephropathy, defined as an increase of 25% or more in serum creatinine within 2 days of contrast.
Results There were no significant group differences in age, sex, incidence of diabetes mellitus, ethnicity, or contrast volume. Baseline serum creatinine was slightly higher but not statistically different in patients receiving sodium bicarbonate treatment (mean [SD], 1.71 [0.42] mg/dL [151.2 {37.1} µmol/L] for sodium chloride and 1.89 [0.69] mg/dL [167.1 {61.0} µmol/L] for sodium bicarbonate; P = .09). The primary end point of contrast-induced nephropathy occurred in 8 patients (13.6%) infused with sodium chloride but in only 1 (1.7%) of those receiving sodium bicarbonate(mean difference, 11.9%; 95% confidence interval [CI], 2.6%-21.2%; P = .02). A follow-up registry of 191 consecutive patients receiving prophylactic sodium bicarbonate and meeting the same inclusion criteria as the study resulted in 3 cases of contrast-induced nephropathy (1.6%; 95% CI, 0%-3.4%).
Conclusion Hydration with sodium bicarbonate before contrast exposure is more effective than hydration with sodium chloride for prophylaxis of contrast-induced renal failure.
INTRODUCTION
The increasing number of diagnostic procedures requiring radiographic contrast has triggered a parallel increase in the incidence of contrast-induced nephropathy, which accounts for more than 10% of hospital-acquired renal failure and is a leading cause of acute renal failure.1-2 Compromise of renal function increases morbidity, mortality, length of hospitalization, and acceleration toward end-stage renal disease.2
Previous strategies to prevent contrast-induced renal failure have been largely unsuccessful.3-6 Reported benefit of the free radical scavenger N-acetylcysteine7-12 supports the hypothesis that contrast-induced renal failure is caused by free-radical generation.13-15 Use of the iso-osmolar contrast agent iodixanol16 and hemofiltration before and after contrast injection17 have been recently described to reduce renal failure following contrast but are expensive strategies that tax the financial resources of health care systems.
All protocols to prevent contrast-induced nephropathy include the infusion of sodium chloride.1-11,16-18 However, in prophylactic hydration, it is possible that the most efficacious anion for sodium is not chloride but bicarbonate. Free-radical formation is promoted by an acidic environment typical of tubular urine19 but is inhibited by the higher pH of normal extracellular fluid.20-21 Because free radicals are postulated to mediate contrast-induced nephropathy,13-15 alkalinizing renal tubular fluid with bicarbonate22 may reduce injury. Pretreatment with sodium bicarbonate is more protective than sodium chloride in animal models of acute renal failure from ischemia23-24 or doxorubicin.25 However, to our knowledge no studies in humans have evaluated the efficacy of sodium bicarbonate vs sodium chloride for prophylaxis against contrast-induced nephropathy. We examined the hypothesis that the bicarbonate anion results in better outcomes than the chloride anion in hydration fluids administered before and after exposure to radiographic contrast.
METHODS
Study Population
This single-center, randomized controlled trial compared infusion of sodium chloride vs sodium bicarbonate as the hydration fluid to prevent renal failure in patients with stable renal insufficiency undergoing diagnostic or interventional procedures requiring radiographic contrast. A subsequent registry was established to additionally test the hypothesis that patients receiving sodium bicarbonate treatment experience a low incidence of contrast-induced renal failure. During the randomized study, consecutive eligible patients scheduled for exposure to the nonionic radiographic contrast agent iopamidol (796 mOsm/kg H2O, 755 mg of iopamidol per milliliter, and 370 mg iodine per milliliter) were considered for enrollment. Eligible patients included individuals aged 18 years or older with stable serum creatinine levels of at least 1.1 mg/dL (97.2 µmol/L) who were scheduled to undergo cardiac catheterization, computed tomography, diagnostic or therapeutic arteriography, or transjugular intrahepatic portal systemic shunt placement. Exclusion criteria included serum creatinine levels of more than 8 mg/dL (>707 µmol/L), change in serum creatinine levels of at least 0.5 mg/dL (44.2 µmol/L) during the previous 24 hours, preexisting dialysis, multiple myeloma, pulmonary edema, uncontrolled hypertension (treated systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg), emergency catheterization, recent exposure to radiographic contrast within 2 days of the study, allergy to radiographic contrast, pregnancy, and administration of dopamine, mannitol, fenoldopam, or N-acetylcysteine during the intended time of the study.
The study was reviewed and approved by the institutional review board of the Carolinas Health Care System. All patients gave written informed consent for participation in the randomization trial or the subsequent registry phase.
Protocol
Patients were identified as study candidates based on preliminary laboratory test results and referral from the physician scheduled to perform the contrast study. Qualified patients who agreed to enter the study were sequentially assigned to 1 of 2 treatment groups by the pharmacy based on a computer-generated randomization schedule. Patients allocated to the sodium chloride group received 154 mEq/L of sodium chloride in 5% dextrose and H2O. Patients allocated to the sodium bicarbonate group received 154 mEq/L of sodium bicarbonate in dextrose and H2O, mixed in the hospital pharmacy by adding 154 mL of 1000 mEq/L sodium bicarbonate to 846 mL of 5% dextrose in H2O, slightly diluting the dextrose concentration to 4.23%.
After appropriate nursing evaluation and initial measurement of blood pressure and weight, the precontrast fluid was administered. The initial intravenous bolus was 3 mL/kg per hour for 1 hour immediately before radiocontrast injection. Following this, patients received the same fluid at a rate of 1 mL/kg per hour during the contrast exposure and for 6 hours after the procedure. For patients weighing more than 110 kg, the initial fluid bolus and drip were limited to those doses administered to a patient weighing 110 kg. Diuretics were routinely held on the day of contrast injection. A basic metabolic panel of serum chemistries was obtained on the morning of the procedure and on postprocedure days 1 and 2, and until any increase of serum creatinine resolved. Urinary pH was measured after infusion of the bolus when the patient next spontaneously voided. No diuretics were administered after a patient received contrast.
This study was partially but not completely blinded. The primary end point, serum creatinine level, was determined in a fully blinded fashion by laboratory personnel who measured serum creatinine by autoanalyzer without knowledge of patient study groups. Patients were not told to which group they were randomized. Although the investigators theoretically could have determined the results of randomization by inspection of solutions infused, their direct contact with patients consisted solely of obtaining informed consent before randomization.
Data Collection and Management
Clinical data were prospectively collected by 3 investigators (G.J.M, W.P.B, L.V.G.), coded, and entered into a computerized database. An independent physician data and safety monitoring board periodically assessed safety throughout the study. The clinical management of the patient was the responsibility of the attending physician.
Study End Points and Statistical Analysis
The primary outcome measure was development of contrast-induced nephropathy, defined by an increase in serum creatinine of 25% or more within 2 days after administration of the radiographic contrast. This definition is identical to that used in a recent large meta-analysis in contrast-induced nephropathy.12 Postcontrast creatinine was assessed the mornings of days 1 and 2. The highest serum creatinine on postcontrast days 1 or 2 was used to calculate the change in serum creatinine (the primary end point), the estimated glomerular filtration rate (a secondary end point) by using the Modification of Diet in Renal Disease Study group formula,26 and incidence of contrast-induced nephropathy.
Before beginning the study, the institution's biostatistician (H.J.N.) estimated the sample size needed for the primary end point of contrast-induced nephropathy, assuming development of contrast-induced renal failure in 15% of the sodium chloride group and 5% of the sodium bicarbonate group.  2 Analysis indicated that a sample size of 260 patients would be required to detect a statistically significant difference with a power of 80% ( = .05).
Tests for significance were conducted using the t test for continuous variables and 2 test or Fisher exact test for categorical variables. All analyses were conducted using SAS software version 8.2 (SAS Institute Inc, Cary, NC). Data are expressed as mean (SD). All tests are 2-tailed, with differences reported as significant if P<.05. The study analysis was modified intention to treat and did not include protocol violators. Ten patients (5 per group) who did not return for follow-up laboratory tests were excluded. Inclusion of their baseline data in the analysis as last-observation-carried-forward was not informative and did not affect the results.
Study Termination
Midway through accumulation of the planned number of study patients, the safety monitor, who was not a study investigator and was blinded to the intervention groups, asked for an interim analysis to ensure that the sodium bicarbonatetreatment group was experiencing an incidence of contrast-induced nephropathy no worse than that of the control group hydrated with sodium chloride. Although there were no prospectively established stopping rules, the study was halted after a review of the data because of ethical concern about continuing to expose the control group to the substantially higher risk of contrast nephropathy associated with sodium chloride hydration. Subsequent eligible patients were treated with the sodium bicarbonate prophylaxis and asked to enroll in a registry.
The registry comprised all patients who met the same inclusion criteria as the study. Outcomes were collected in the same way as the randomized trial. To simplify the sodium bicarbonate preparation for registry patients, the sodium bicarbonate solution was prepared by adding 3 ampules (150 mEq) of sodium bicarbonate to 1 L of 5% dextrose in H2O, yielding a 130-mEq/L concentration of sodium bicarbonate and 4.35% dextrose. To obtain the same sodium bicarbonate load as those patients in the randomized phase, these registry patients received a 3.5-mL/kg initial bolus for 1 hour immediately before contrast injection, followed by an infusion of 1.18 mL/kg per hour thereafter for 6 hours.
RESULTS
Randomized Study
Between September 16, 2002, and June 17, 2003, 137 patients were randomized to receive sodium bicarbonate (n = 69) or sodium chloride (n = 68), with 119 patients completing the study (Figure 1). A total of 18 patients did not complete the study. Five outpatient study patients in each group neglected to follow instructions to return for follow-up laboratory studies but had good urine output at discharge. Although measurements of serum creatinine are not available for these individuals, none are known to have developed clinical renal failure following contrast exposure. Eight patients were protocol violations: 5 were not candidates because serum creatinine values were too low ( 1.0 mg/dL [88.4 µmol/L]) on the morning of the procedure, 2 had received another prophylactic agent (dopamine or N-acetylcysteine), and 1 was identified before contrast injection as having an increasing serum creatinine level from bladder outlet obstruction. One patient's prophylaxis regimen was arbitrarily changed by the attending physician from sodium chloride to sodium bicarbonate but this patient was included in the sodium chloride group analysis based on the intention-to-treat principle.
|
|
|
|
Figure 1. Study Flow and Distribution of Procedures
To convert serum creatinine to µmol/L, multiply by 88.4.
|
|
|
Characteristics of the 119 patients completing the study are shown in Table 1. There were no statistically significant differences between the groups in age, sex, ethnicity, incidence of diabetes mellitus, or weight. Cardiac catherization was the most frequent radiocontrast procedure in this study (Figure 1). Treatment groups did not differ significantly by mean volume of contrast administered or in volumes of contrast received by individuals in either treatment group undergoing cardiac catheterization, computed tomography, or other miscellaneous procedures (Table 2). The mean baseline serum creatinine was slightly but not statistically higher (P = .09) and the glomerular filtration rate lower in patients receiving sodium bicarbonate treatment compared with those patients receiving sodium chloride. More patients with severe renal insufficiency (serum creatinine, 2.5 mg/dL [221 µmol/L]) were randomized to receive sodium bicarbonate (n = 8) than sodium chloride (n = 2) (Figure 2). Because elevated serum creatinine is an important risk factor for development of contrast-induced nephropathy,1-2 our nonstratified randomization procedure could have biased the study outcome against patients receiving sodium bicarbonate.
|
|
|
|
Table 1. Baseline Clinical and Biochemical Characteristics of Patients Receiving Either Sodium Chloride or Sodium Bicarbonate
|
|
|
|
|
|
|
Table 2. Procedures, Contrast Volumes, and Biochemical Responses in Patients Receiving Either Sodium Chloride or Sodium Bicarbonate*
|
|
|
|
|
|
|
Figure 2. Serum Creatinine Concentrations Before and After Contrast
Blue heavy lines represent cases of contrast-induced renal failure. Dotted line indicates threshold for severe renal insufficiency (serum creatinine 2.5 mg/dL [221 µmol/L]). To convert serum creatinine to µmol/L, multiply by 88.4. Error bars indicate 95% confidence intervals. Mean serum creatinine estimates for sodium chloride hydration before and after contrast are 1.71 and 1.75 mg/dL, respectively, and for sodium bicarbonate hydration, 1.89 and 1.82 mg/dL, respectively.
|
|
|
Postcontrast data for serum creatinine levels increased for those patients receiving sodium chloride but decreased slightly for patients receiving sodium bicarbonate. Despite a higher mean baseline serum creatinine and a higher number of individuals with a baseline creatinine level of at least 2.5 mg/dL (221 µmol/L), the group receiving sodium bicarbonate treatment incurred only a 1.7% (1 of 60) incidence of contrast-induced nephropathy compared with 13.6% (8 of 59) in patients who received sodium chloride (mean difference, 11.9%; 95% confidence interval [CI], 2.6%-21.2%; P = .02) (Table 2). Post hoc analysis revealed that the percentage change in glomerular filtration rate after contrast (Figure 3) was significantly improved in patients receiving sodium bicarbonate treatment (+8.5%) compared with those receiving sodium chloride (–0.1%) (mean difference, –8.6%; 95% CI, –17.0% to –0.2%; P = .02). When results were analyzed by another common definition of contrast nephropathy, at least 0.5 mg/dL (44.2 µmol/L) change in serum creatinine, 7 (11.9%) of 59 patients who were treated with sodium chloride developed contrast nephropathy vs only 1 (1.7%) of 60 who received sodium bicarbonate (mean difference, 10.2%; 95% CI, 1.3%-19.1%; P = .03). The absolute risk reduction of contrast-induced nephropathy (defined as 25% change in serum creatinine), using sodium bicarbonate compared with sodium chloride was 11.9%, resulting in a number needed to treat of 8.4 patients to prevent 1 case of renal failure.
|
|
|
|
Figure 3. Percentage Change in Estimated Glomerular Filtration Rate in Randomized Patients Following Contrast
Dotted line indicates threshold for contrast-induced nephropathy. The glomerular filtration rate is estimated using the method described by Levey et al.26 Error bars indicate 95% confidence intervals. Mean change in glomerular filtration rate estimates for sodium chloride and sodium bicarbonate hydration are –0.1% and 8.5%, respectively.
|
|
|
All cases of contrast-induced nephropathy occurred in patients undergoing cardiac catheterization (8 [17%] of 48 patients who were treated with sodium chloride and 1 [2%] of 49 patients who were treated with sodium bicarbonate). When patients undergoing cardiac catheterization were analyzed independently, the benefit of sodium bicarbonate treatment was even larger (incidence of contrast-induced nephropathy, 16.7% for sodium chloride vs 2.0% for sodium bicarbonate; mean difference, 14.7%; 95% CI, 3.4%-25.9%; P = .02). All individuals with contrast-induced nephropathy experienced prolonged hospitalization as a consequence of this complication but none required dialysis. Of the 9 randomized patients who experienced contrast-induced nephropathy, the mean (SD) baseline serum creatinine was 1.66 (0.56) mg/dL (146.7 [49.5] µmol/L) among the 8 patients receiving sodium chloride and 2.1 mg/dL (185.6 µmol/L) in the single patient treated with sodium bicarbonate. In the cases of contrast-induced nephropathy, the 8 patients who received sodium chloride had a mean (SD) contrast volume of 151 (50) mL (range, 100-250), not statistically different from the overall sodium chloride cohort. The only patient in the sodium bicarbonate treatment group who developed contrast-induced nephropathy received only 65 mL of contrast but experienced 24 hours of profound hypotension associated with an acute myocardial infarction. After restoration of this patient's hemodynamic stability, the serum creatinine level returned to the baseline of 2.1 mg/dL (185.6 µmol/L) 4 days after contrast.
In each group, bolus administration of hydration fluid caused a moderate increase in both systolic and diastolic blood pressures that was not significantly different between groups (Table 2). The medical records of all patients who had a serum creatinine level increase of 25% or more were reviewed in detail. Other than the single patient in the sodium bicarbonate treatment group who developed contrast-induced nephropathy, no other patient was found to have an alternative explanation for deterioration of serum creatinine. No patient developed clinical heart failure or respiratory distress. One patient in the sodium bicarbonate treatment group had a blood pressure increase of more than 30 mm Hg with the administration of the bolus. The fluid bolus administration was discontinued and diuretic therapy was administered before proceeding with contrast injection. Following diuretics and contrast, the infusion was continued and the patient did not develop contrast-induced nephropathy.
Urine pH measurements after the initial bolus of fluid confirmed that patients receiving sodium bicarbonate experienced urinary alkalinization (Table 2). A small but significant increase in serum bicarbonate occurred in patients receiving sodium bicarbonate. There was a small nonsignificant decrease in serum potassium in the sodium bicarbonate group, indicating that the alkaline load from sodium bicarbonate did not induce a decrease in serum potassium sufficient to create a risk for disturbances of cardiac rhythm.
Registry Phase
When randomization was discontinued, all subsequent patients meeting the original inclusion criteria were treated with sodium bicarbonate and asked to enroll in the registry until February 8, 2004. The demographic data of these 191 patients were not statistically different from either of the randomized groups. The mean (SD) serum creatinine level of registry patients was 1.79 (0.62) mg/dL (158.2 [54.8] µmol/L). The mean (SD) percentage change in serum creatinine was 0% (13.5%) and the mean (SD) percentage change in estimated glomerular filtration rate was + 2.5% (16.9%). Contrast-induced nephropathy occurred in 3 (1.6%) of 191 patients (95% CI, 0%-3.4%).
COMMENT
In this study, we showed that replacing chloride ion with bicarbonate as the anion in sodium-containing hydration fluids significantly reduced nephropathy following radiographic contrast injection. In a recent meta-analysis, the incidence of contrast-induced nephropathy ranged from 2% to 26% in patients receiving N-acetylcysteine plus sodium chloride and 11% to 45% in those patients administered sodium chloride hydration alone.12 The cumulative incidence of contrast-induced nephropathy in our patients in the sodium bicarbonate treatment group (1.7% in randomized patients and 1.6% in the subsequent registry) is equal to or less than the lowest rate of injury reported with N-acetylcysteine12 and is far less than the published experience in patients hydrated with sodium chloride.1-11,16-18These studies were performed with so-called nonionic low osmotic contrast agents of approximately 600 to 900 mOsm/L, similar to that of the iopamidol used in our study (796 mOsm/L). The subsequent data registry further confirms that preprocedure intravenous administration of sodium bicarbonate reduces renal injury from radiographic contrast. We envision that sodium bicarbonate could also be combined with other agents such as N-acetylcysteine, which alone does not always prevent contrast nephropathy.27-30
The apparent success of sodium bicarbonate in reducing contrast-induced nephropathy is not likely the result of better volume expansion from sodium bicarbonate31-32 but is consistent with the hypothesis that contrast injury is from free radicals13-15 generated within the acid environment of the renal medulla. Contrast-induced nephropathy appears to be caused by the hyperosmolar nature of most contrast agents.1, 3, 16 Hyperosmolar stress triggers prompt cellular generation of reactive oxygen species.33-34 Effects from hyperosmolar stress might be compounded in the renal medulla, which is normally deficient in oxygen, with a PaO2 of 10 to 20 mm Hg.35 Radiocontrast causes vasoconstriction,13-14,36 a decrease in renal blood flow, and a further increase in medullary hypoxia37 that is exacerbated by the already compromised renal circulation in diabetes mellitus or preexisting kidney damage,35 or by nonsteroidal anti-inflammatory agents, which block normal prostaglandin enhancement of medullary blood flow.37-38 Paradoxically, decreased tissue oxygen tension promotes mitochondrial generation of reactive oxygen species.39-40 Oxidant stress could also be magnified by the enhanced neutrophil adherence and emigration that is stimulated by local hypoxia.41 Thus, local conditions in the renal medulla after contrast favor oxidant injury, a hypothesis supported by the abrupt increase of malondialdehyde in renal venous plasma immediately following contrast-induced vasoconstriction and the reduction in experimental contrast-induced nephropathy by superoxide dismutase or allopurinol.13-15 The superoxide (O2-)–driven Haber-Weiss reaction,
Fe3+ + O2– Fe2+ + O2
Fe2+ + H2O2 Fe3+ +  OH + OH–
accounts for free-radical production in many oxidant-mediated human diseases.20 The reaction is catalyzed by minute amounts of iron in the biologic environment and is most active at acid pH (pKa = 4.9). However, at neutral pH, uncomplexed ferric ions precipitate as insoluble ferric hydroxides,21 reducing the production of injurious hydroxyl (.OH) radicals.20 By increasing medullary pH, bicarbonate might protect from oxidant injury by slowing Haber-Weiss radical production. Also, superoxide generated by ischemia might react with medullary nitric oxide to form the potent oxidant peroxynitrite.42 At physiologic concentrations, bicarbonate scavenges peroxynitrite and other reactive species generated from nitric oxide.43 Thus, several oxidant mechanisms of renal injury might be disrupted by sodium bicarbonate.
The potential effect of sodium bicarbonate on these events is not surprising in light of pH conditions within the nephron. Near the end of the proximal tubule in the medulla, as a consequence of active reabsorption, the tubular bicarbonate concentration has declined to about 6 mEq/L, and the tubular fluid pH is approximately 6.5.19 In the descending Loop of Henle, water and chloride are passively reabsorbed,19 and urine pH increases to about 7.4 at the tip of the papilla, which is spared from contrast nephropathy,35 suggesting that higher pH is protective. In fact, patients with enhanced urinary acid excretion from high aldosterone (eg, dehydration, congestive heart failure, nephrotic syndrome, and cirrhosis) have increased risk of contrast-induced nephropathy.3 The beneficial effect of higher proximal tubular pH is supported by a report that acetazolamide, which blocks proximal tubular bicarbonate reabsorption, is protective in a rat model of contrast-induced renal failure.44
A recent study advocated hemofiltration before and after contrast to prevent contrast-induced renal failure from coronary angiography.17 All dialysis procedures are alkalinizing and as reported, this study left open the question of whether its major benefit was from the increased clearance conferred by this invasive and expensive procedure or by the infusion of alkalinizing replacement solution.
Our study has several limitations. The results are from a single institution, sample sizes are small although adequately powered, and dropouts occurred in both study groups from outpatient participants who failed to return for postcontrast measurement of serum creatinine. Also, the study was terminated early when significant differences were found between groups, because of ethical concern about continuing to expose control patients to the substantially higher risk of contrast nephropathy associated with sodium chloride hydration alone. Nevertheless, the results suggest that hydration with sodium bicarbonateis efficacious and practical, requiring pretreatment only an hour before contrast injection. Although confirmation in a larger multi-institution study would be appropriate, infusion of sodium bicarbonatemay provide an inexpensive, safe, practical, and simple method for preventing contrast-induced renal failure.
AUTHOR INFORMATION
| |
Corresponding Author: Thomas P. Kennedy, MD, MPH, Department of Internal Medicine, Carolinas Medical Center, MEB 507, PO Box 38162, Charlotte, NC 28232 (tkennedy{at}carolinas.org).
Author Contributions: Drs Merten and Burgess had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Merten, Burgess, Gray, Holleman, Bersin, Moore, Kennedy.
Acquisition of data: Merten, Burgess, Gray.
Analysis and interpretation of data: Merten, Burgess, Gray, Roush, Kowalchuk, Moore, Simonton, Rittase, Norton, Kennedy.
Drafting of the manuscript: Merten, Burgess, Gray, Roush, Rittase, Norton, Kennedy.
Critical revision of the manuscript for important intellectual content: Merten, Gray, Holleman, Kowalchuk, Bersin, Moore, Simonton, Norton, Kennedy.
Statistical expertise: Merten, Burgess, Norton.
Obtained funding: Merten.
Administrative, technical, or material support: Merten, Burgess, Gray, Holleman, Roush, Bersin, Moore, Rittase, Kennedy.
Supervision: Merten, Burgess, Gray, Kowalchuk, Bersin, Moore, Simonton, Rittase.
Funding/Support: This study was supported in part by Carolinas Medical Center, who supplied the contrast reagent and hydration fluids used in our study, and provided salary support for Greg J. Merten, MD, Lee V. Gray, MD, Robert A. Rittase, PharmD, H. James Norton, PhD, and Thomas P. Kennedy, MD, who were full-time institutional employees at the time this study was conducted. The study received no funding from manufacturers of contrast agents or suppliers of saline or bicarbonate.
Role of the Sponsor: The administration of Carolinas Medical Center was not involved in study analysis or interpretation, and had no role in the drafting of the manuscript.
Author Affiliations: Departments of Internal Medicine (Drs Merten, Gray, and Kennedy), Radiology (Dr Van Moore), Clinical Pharmacy (Dr Rittase), Biostatistics (Dr Norton), Sanger Cardiology (Drs Kowalchuk, Bersin, and Simonton), Sanger Cardiovascular Surgery (Drs Holleman and Roush), and Metrolina Nephrology (Dr Burgess), Carolinas Medical Center, Charlotte, NC. Dr Merten is now with the Division of Nephrology, Mayo Clinic, Rochester, Minn.
REFERENCES
1. Briguiori C, Tavano D, Colombo A. Contrast agent-associated nephrotoxicity. Prog Cardiovasc Dis. 2003;45:493-503.
FULL TEXT
|
ISI
| PUBMED
2. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375.
FULL TEXT
|
ISI
| PUBMED
3. Baker CSR, Baker LRI. Prevention of contrast nephropathy after cardiac catheterization. Heart. 2001;85:361-362.
FREE FULL TEXT
4. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
FREE FULL TEXT
5. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int. 1995;47:254-261.
ISI
| PUBMED
6. Stone GE, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290:2284-2291.
FREE FULL TEXT
7. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by N-acetylcysteine. N Engl J Med. 2000;343:180-184.
FREE FULL TEXT
8. Skyu KG, Cheng JJ, Kuan P. N-acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383-1388.
FREE FULL TEXT
9. Kay J, Chow WH, Chan TM, et al. N-acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289:553-558.
FREE FULL TEXT
10. Baker CS, Wragg A, Kuman S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114-2118.
FREE FULL TEXT
11. Safirstein R, Andrade L, Vieira JM. N-acetylcysteine and nephrotoxic effects of RC agents: a new use for an old drug. N Engl J Med. 2000;343:210-212.
FREE FULL TEXT
12. Birck R, Krzossk S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
FULL TEXT
|
ISI
| PUBMED
13. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990;258:F115-F120.
ISI
| PUBMED
14. Bakris GL, Gabaer AO, Jones JD. Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology. 1990;175:57-60.
FREE FULL TEXT
15. Katholi RE, Woods T Jr, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32:64-71.
ISI
| PUBMED
16. Aspelin P, Aubry P, Fransson S-G, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-499.
FREE FULL TEXT
17. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333-1340.
FREE FULL TEXT
18. Teruel JL, Maracen R, Herrero JA, Ortuno FJ. An easy and effective procedure to prevent radiocontrast nephrotoxicity in high-risk patients [letter]. Nephron. 1989;51:282.
ISI
| PUBMED
19. Alpern RJ. Renal acidification mechanisms. In: Brenner BM, ed. The Kidney. 6th ed. Philadelphia, Pa: WB Saunders; 2000:455-519.
20. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human diseases: an overview. Methods Enzymol. 1990;186:1-85.
FULL TEXT
| PUBMED
21. Cohen G. The Fenton reaction. In: Greenwald RA, ed. CRC Handbook of Methods for Oxygen Radical Research. Boca Raton, Fla: CRC Press Inc; 1985:55-64.
22. Lindinger MI, Franklin TW, Lands LC, et al. NaHCO3 and KHCO3 ingestion rapidly increases renal electrolyte excretion in humans. J Appl Physiol. 2000;88:540-550.
FREE FULL TEXT
23. Atkins JL. Effect of sodium bicarbonate preloading on ischemic renal failure. Nephron. 1986;44:70-74.
ISI
| PUBMED
24. Sporer H, Lang F, Oberleithner H, et al. Inefficacy of bicarbonate infusions on the source of post-ischemic acute renal failure in the rat. Eur J Clin Invest. 1981;11:311-315.
ISI
| PUBMED
25. Baroni EA, Costa RS, Volpini R, et al. Sodium bicarbonate treatment reduces renal injury, renal production of transforming growth factor-beta, and urinary growth factor-beta excretion in rats with doxorubicin-induced nephropathy. Am J Kidney Dis. 1999;34:328-337.
ISI
| PUBMED
26. Levey AS, Bosch JP, Lewis JB, et al, and The Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
FREE FULL TEXT
27. Vallero A, Cesano G, Pozzato M, et al. Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC). G Ital Nefrol. 2002;19:529-533.
PUBMED
28. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002;57:279-283.
FULL TEXT
|
ISI
| PUBMED
29. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202-2207.
FULL TEXT
|
ISI
| PUBMED
30. Boccalandro F, Amhad M, Smalling RW, et al. Oral acetylcyteine does not protect renal function from moderate to high doses of intravenous RC. Catheter Cardiovasc Interv. 2003;58:336-341.
FULL TEXT
|
ISI
| PUBMED
31. Julian BA, Krzyzaniak KE, Anderson JE, et al. Renin and aldosterone responses to acute NaCl or NaHCO3 loading in man. J Lab Clin Med. 1982;100:261-268.
ISI
| PUBMED
32. Kotchen TA, Luke RG, Cobern EO, et al. Effect of chloride on renin and blood pressure responses to sodium chloride. Ann Intern Med. 1983;98:817-822.
ISI
| PUBMED
33. Loitsch SM, von Mallinckrodt C, Kippenberger S, et al. Reactive oxygen intermediates are involved in IL-8 production induced by hyperosmotic stress in human bronchial epithelial cells. Biochem Biophys Res Commun. 2000;276:571-578.
FULL TEXT
|
ISI
| PUBMED
34. Qin S, Ding J, Takano T, et al. Involvement of receptor aggregation and reactive oxygen species in osmotic stress-induced activation in B cells. Biochem Biophys Res Commun. 1999;262:231-236.
FULL TEXT
|
ISI
| PUBMED
35. Brezia M, Rosen S. Hypoxia of the renal medulla: its implications for disease. N Engl J Med. 1995;332:647-655.
FREE FULL TEXT
36. Murphy ME, Tublin ME, Li S. Influence of contrast media on the response of rat renal arteries to endothelin and nitric oxide: influence of contrast media. Invest Radiol. 1998;33:356-365.
FULL TEXT
|
ISI
| PUBMED
37. Agmon Y, Peleg H, Greenfield Z, et al. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest. 1994;94:1069-1075.
ISI
| PUBMED
38. Heyman SN, Brezia M, Epstein FH, et al. Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int. 1991;40:632-642.
ISI
| PUBMED
39. Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1 during hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000;275:25130-25138.
FREE FULL TEXT
40. Dada LA, Chandel NS, Ridge KM, et al. Hypoxia-induced endocytosis of Na,K-ATPase in alveolar epithelial cells is mediated by mitochondrial reactive oxygen species and PKC-zeta. J Clin Invest. 2003;111:1057-1064.
FULL TEXT
|
ISI
| PUBMED
41. Gonzalez NC, Wood JG. Leukocyte-endothelial interactions in environmental hypoxia. Adv Exp Med Biol. 2001;502:39-60.
ISI
| PUBMED
42. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol. 1995;268:L699-L722.
ISI
| PUBMED
43. Caulfield JL, Singh SP, Wishnok JS, et al. Bicarbonate inhibits N-nitrosation in oxygenated nitric oxide solutions. J Biol Chem. 1996;271:25859-25863.
FREE FULL TEXT
44. Novikov M, Molitoris B, Campos S, et al. Renoprotective properties of acetazolamide in a rat model of contrast media induced renal failure [abstract]. J Am Soc Nephrol. 2003;14:345A.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate
L. Shavit, M. Lifschitz, J. Plaksin, and I. N. Slotki
JAMA. 2004;292(12):1428.
EXTRACT
| FULL TEXT
Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate
Robert E. Siegel
JAMA. 2004;292(12):1428.
EXTRACT
| FULL TEXT
Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium–Induced Nephropathy
William Burgess, Gregory J. Merten, and Robert A. Rittase
JAMA. 2009;301(4):377.
EXTRACT
| FULL TEXT
Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium–Induced Nephropathy—Reply
Somjot S. Brar, Albert Yuh-Jer Shen, and Michael B. Jorgensen
JAMA. 2009;301(4):379-380.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Prevention of Radiocontrast Nephropathy: Back to Basics
Glenn M. Chertow
JAMA. 2004;291(19):2376-2377.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Systematic Review: Sodium Bicarbonate Treatment Regimens for the Prevention of Contrast-Induced Nephropathy
Zoungas et al.
ANN INTERN MED 2009;151:631-638.
ABSTRACT
| FULL TEXT
Sodium Bicarbonate for the Prevention of Contrast Induced-Acute Kidney Injury: A Systematic Review and Meta-analysis
Brar et al.
CJASN 2009;4:1584-1592.
ABSTRACT
| FULL TEXT
Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis
Hoste et al.
Nephrol Dial Transplant 2009;0:gfp389v1-gfp389.
ABSTRACT
| FULL TEXT
The Relative Renal Safety of Iodixanol Compared With Low-Osmolar Contrast Media: A Meta-Analysis of Randomized Controlled Trials
Reed et al.
J Am Coll Cardiol Intv 2009;2:645-654.
ABSTRACT
| FULL TEXT
Defining Contrast-Induced Nephropathy
Palevsky
CJASN 2009;4:1151-1153.
FULL TEXT
Iodixanol, Constriction of Medullary Descending Vasa Recta, and Risk for Contrast Medium-induced Nephropathy
Sendeski et al.
Radiology 2009;251:697-704.
ABSTRACT
| FULL TEXT
Reporting Standards for Angioplasty and Stent-Assisted Angioplasty for Intracranial Atherosclerosis
Schumacher et al.
Stroke 2009;40:e348-e365.
ABSTRACT
| FULL TEXT
Renal Protective Effects and the Prevention of Contrast-Induced Nephropathy by Atrial Natriuretic Peptide
Morikawa et al.
J Am Coll Cardiol 2009;53:1040-1046.
ABSTRACT
| FULL TEXT
Soluble Thrombomodulin Protects Ischemic Kidneys
Sharfuddin et al.
J. Am. Soc. Nephrol. 2009;20:524-534.
ABSTRACT
| FULL TEXT
Contrast-Induced Acute Kidney Injury: Specialty-Specific Protocols for Interventional Radiology, Diagnostic Computed Tomography Radiology, and Interventional Cardiology
Goldfarb et al.
Mayo Clin Proc. 2009;84:170-179.
ABSTRACT
| FULL TEXT
Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium-Induced Nephropathy
Burgess et al.
JAMA 2009;301:377-377.
FULL TEXT
Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium-Induced Nephropathy--Reply
Brar et al.
JAMA 2009;301:379-380.
FULL TEXT
Acute Kidney Injury in the Critically Ill
Muther
ACCP Crit Care Med Brd Rev 2009;20:507-522.
FULL TEXT
CHAPTER 15b Cardiovascular Problems in Chronic Kidney Disease
Ritz and Remppis
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT
| FULL TEXT
Endovascular Approaches to Complex Thoracic Aortic Disease
Hughes et al.
SEMIN CARDIOTHORAC VASC ANESTH 2008;12:298-319.
ABSTRACT
The prevention of acute kidney injury: an in-depth narrative review Part 1: volume resuscitation and avoidance of drug- and nephrotoxin-induced AKI
Lameire et al.
NDT Plus 2008;1:392-402.
ABSTRACT
| FULL TEXT
Consensus conference on the management of tumor lysis syndrome
Tosi et al.
haematol 2008;93:1877-1885.
ABSTRACT
| FULL TEXT
Contrast agents and renal cell apoptosis
Romano et al.
Eur Heart J 2008;29:2569-2576.
ABSTRACT
| FULL TEXT
Effect of Preoperative Renal Dysfunction on Mortality and Postoperative Renal Failure Following Endovascular Abdominal Aortic Aneurysm Repair
Soong et al.
VASC ENDOVASCULAR SURG 2008;42:427-432.
ABSTRACT
Mortality Associated With Nephropathy After Radiographic Contrast Exposure
From et al.
Mayo Clin Proc. 2008;83:1095-1100.
ABSTRACT
| FULL TEXT
Sodium Bicarbonate vs Sodium Chloride for the Prevention of Contrast Medium-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Randomized Trial
Brar et al.
JAMA 2008;300:1038-1046.
ABSTRACT
| FULL TEXT
Incidence and Outcomes of Contrast-Induced AKI Following Computed Tomography
Weisbord et al.
CJASN 2008;3:1274-1281.
ABSTRACT
| FULL TEXT
Sodium Bicarbonate Versus Saline for the Prevention of Contrast-Induced Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention
Maioli et al.
J Am Coll Cardiol 2008;52:599-604.
ABSTRACT
| FULL TEXT
Contrast-Induced Nephropathy: Contrast Material Not Required?
Baumgarten and Ellis
Am. J. Roentgenol. 2008;191:383-386.
ABSTRACT
| FULL TEXT
Evaluation and Initial Management of Acute Kidney Injury
Himmelfarb et al.
CJASN 2008;3:962-967.
ABSTRACT
| FULL TEXT
Prevention, Incidence, and Outcomes of Contrast-Induced Acute Kidney Injury
Weisbord et al.
Arch Intern Med 2008;168:1325-1332.
ABSTRACT
| FULL TEXT
Does prophylactic haemodialysis protect kidney function after angiography?
Tepel
Nephrol Dial Transplant 2008;23:1473-1475.
FULL TEXT
Contrast-Induced Acute Kidney Injury
McCullough
J Am Coll Cardiol 2008;51:1419-1428.
ABSTRACT
| FULL TEXT
Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes
Kane et al.
Nephrol Dial Transplant 2008;23:1233-1240.
ABSTRACT
| FULL TEXT
Renal impairment
Geddes and Baxter
Imaging 2008;20:1-19.
ABSTRACT
| FULL TEXT
Cardiovascular Literature--Beyond Nephrology
Ritz
CJASN 2008;3:317-323.
FULL TEXT
Meta-analysis: Effectiveness of Drugs for Preventing Contrast-Induced Nephropathy
Kelly et al.
ANN INTERN MED 2008;148:284-294.
ABSTRACT
| FULL TEXT
Response to Letters Regarding Article, "Cardiac Angiography in REnally Impaired Patients (CARE) Study: A Randomized Double-Blind Trial of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease"
Solomon et al.
Circulation 2008;117:e167-e167.
FULL TEXT
Clinical research of kidney diseases IV: standard regression models
Ravani et al.
Nephrol Dial Transplant 2008;23:475-482.
FULL TEXT
Myocardial Revascularization with Percutaneous Devices
Wilson and Willerson
Card Surg Adult 2008;3:573-598.
FULL TEXT
Sodium Bicarbonate is Associated with an Increased Incidence of Contrast Nephropathy: A Retrospective Cohort Study of 7977 Patients at Mayo Clinic
From et al.
CJASN 2008;3:10-18.
ABSTRACT
| FULL TEXT
Prevention of Contrast-Induced Nephropathy with Volume Expansion
Weisbord and Palevsky
CJASN 2008;3:273-280.
ABSTRACT
| FULL TEXT
ACCF/AHA 2007 Clinical Competence Statement on vascular imaging with computed tomography and magnetic resonance
Kramer et al.
Vasc Med 2007;12:359-378.
CT Angiography versus MR Angiography in the Evaluation of Acute Neurovascular Disease
Truwit and Bowen
Radiology 2007;245:362-366.
FULL TEXT
Renal Failure After Cardiac Surgery: Timing of Cardiac Catheterization and Other Perioperative Risk Factors
Del Duca et al.
Ann. Thorac. Surg. 2007;84:1264-1271.
ABSTRACT
| FULL TEXT
Contrast-induced nephropathy
Wong and Irwin
Br J Anaesth 2007;99:474-483.
ABSTRACT
| FULL TEXT
ACCF/AHA 2007 Clinical Competence Statement on Vascular Imaging With Computed Tomography and Magnetic Resonance: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training Developed in Collaboration With the Society of Atherosclerosis Imaging and Prevention, the Society for Cardiovascular Angiography and Interventions, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society for Vascular Medicine and Biology
Kramer et al.
J Am Coll Cardiol 2007;50:1097-1114.
FULL TEXT
Response to Letter Regarding Article, "Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategies"
Briguori et al.
Circulation 2007;116:e311-e311.
FULL TEXT
Contrast media nephropathy--how to diagnose and how to prevent?
Solomon
Nephrol Dial Transplant 2007;22:1812-1815.
FULL TEXT
Anaesthetic considerations for interventional neuroradiology
Varma et al.
Br J Anaesth 2007;99:75-85.
ABSTRACT
| FULL TEXT
Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures
Onbasili et al.
Heart 2007;93:698-702.
ABSTRACT
| FULL TEXT
Safety of Same-Day Coronary Angiography in Patients Undergoing Elective Valvular Heart Surgery
Brown et al.
Mayo Clin Proc. 2007;82:572-574.
ABSTRACT
| FULL TEXT
Visipaque (iodixanol) and hexabrix (ioxaglate) in renal insufficiency.
Deray
J Am Coll Cardiol 2007;49:1668-1668.
FULL TEXT
Reply.
Jo et al.
J Am Coll Cardiol 2007;49:1669-1670.
FULL TEXT
The Reno-Protective Effect of Hydration With Sodium Bicarbonate Plus N-Acetylcysteine in Patients Undergoing Emergency Percutaneous Coronary Intervention: The RENO Study
Recio-Mayoral et al.
J Am Coll Cardiol 2007;49:1283-1288.
ABSTRACT
| FULL TEXT
Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategies
Briguori et al.
Circulation 2007;115:1211-1217.
ABSTRACT
| FULL TEXT
Pharmacologic Treatment of Acute Kidney Injury: Why Drugs Haven't Worked and What Is on the Horizon
Jo et al.
CJASN 2007;2:356-365.
ABSTRACT
| FULL TEXT
BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction
Djamali et al.
Am. J. Physiol. Renal Physiol. 2007;292:F513-F522.
ABSTRACT
| FULL TEXT
Clinical Impact of Chronic Renal Insufficiency on Endovascular Aneurysm Repair
Park et al.
VASC ENDOVASCULAR SURG 2007;40:437-445.
ABSTRACT
Prevention of Acute Renal Failure
Venkataraman and Kellum
Chest 2007;131:300-308.
ABSTRACT
| FULL TEXT
Diagnostic Pathways in Acute Pulmonary Embolism: Recommendations of the PIOPED II Investigators
Stein et al.
Radiology 2007;242:15-21.
FULL TEXT
N-Acetylcysteine and Sodium Bicarbonate Versus N-Acetylcysteine and Standard Hydration for the Prevention of Radiocontrast-Induced Nephropathy Following Coronary Angiography
Schmidt et al.
The Annals of Pharmacotherapy 2007;41:46-50.
ABSTRACT
| FULL TEXT
Associations of Increases in Serum Creatinine with Mortality and Length of Hospital Stay after Coronary Angiography
Weisbord et al.
J. Am. Soc. Nephrol. 2006;17:2871-2877.
ABSTRACT
| FULL TEXT
Acute renal failure induced by contrast medium: steps towards prevention.
Mathew et al.
BMJ 2006;333:539-540.
FULL TEXT
Studying the Prevention of Acute Kidney Injury: Lessons from an 18th-Century Mathematician
Chertow et al.
CJASN 2006;1:1124-1127.
FULL TEXT
Use of Gadolinium-Based Angiography for Renal Artery Stenting in a Patient With Renal Insufficiency: A Case Report
Mannebach et al.
ANGIOLOGY 2006;57:526-529.
ABSTRACT
A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients
Dussol et al.
Nephrol Dial Transplant 2006;21:2120-2126.
ABSTRACT
| FULL TEXT
Medical Care of Kidney Transplant Recipients after the First Posttransplant Year
Djamali et al.
CJASN 2006;1:623-640.
ABSTRACT
| FULL TEXT
Prophylaxis Strategies for Contrast-Induced Nephropathy
Pannu et al.
JAMA 2006;295:2765-2779.
ABSTRACT
| FULL TEXT
Preventing nephropathy induced by contrast medium.
Gross et al.
NEJM 2006;354:1853-1855.
FULL TEXT
Contrast-Induced Nephropathy: A Clinical and Evidence-Based Approach
Tepel et al.
Circulation 2006;113:1799-1806.
FULL TEXT
Coronary Revascularization in Diabetic Chronic Kidney Disease/End-Stage Renal Disease: A Nephrologist's Perspective
Williams
CJASN 2006;1:209-220.
FULL TEXT
Update in nephrology and hypertension.
Kimmel
ANN INTERN MED 2006;144:281-285.
FULL TEXT
Update in Hospital Medicine
Wiese and Holman
ANN INTERN MED 2006;144:195-200.
FULL TEXT
Management of acute renal failure
Fry and Farrington
Postgrad. Med. J. 2006;82:106-116.
ABSTRACT
| FULL TEXT
Preventing Nephropathy Induced by Contrast Medium
Barrett and Parfrey
NEJM 2006;354:379-386.
FULL TEXT
Additional Information
JAMA 2005;294:E1-E3.
FULL TEXT
Renal Failure Secondary to Acute Tubular Necrosis: Epidemiology, Diagnosis, and Management
Gill et al.
Chest 2005;128:2847-2863.
ABSTRACT
| FULL TEXT
Preventing in-hospital cardiac and renal complications in high-risk PCI patients
Brinker et al.
Eur Heart J Suppl 2005;7:G13-G24.
ABSTRACT
| FULL TEXT
Where do we stand with renovascular hypertension?
Claus et al.
Nephrol Dial Transplant 2005;20:1495-1498.
FULL TEXT
Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies
Goldenberg and Matetzky
CMAJ 2005;172:1461-1471.
ABSTRACT
| FULL TEXT
Incidence of contrast nephropathy from cerebral CT angiography and CT perfusion imaging
Josephson et al.
Neurology 2005;64:1805-1806.
ABSTRACT
| FULL TEXT
Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: The CADILLAC Risk Score
Halkin et al.
J Am Coll Cardiol 2005;45:1397-1405.
ABSTRACT
| FULL TEXT
The year in interventional cardiology
O'Neill et al.
J Am Coll Cardiol 2005;45:1117-1134.
FULL TEXT
Contrast-Induced Nephropathy
Gleeson and Bulugahapitiya
Am. J. Roentgenol. 2004;183:1673-1689.
FULL TEXT
Dopamine-1 Receptor Agonist: Renal Effects and Its Potential Role in the Management of Radiocontrast-Induced Nephropathy
Asif et al.
J Clin Pharmacol 2004;44:1342-1351.
ABSTRACT
| FULL TEXT
Contrast nephropathy: Review focusing on prevention
Maeder et al.
J Am Coll Cardiol 2004;44:1763-1771.
ABSTRACT
| FULL TEXT
Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction
Marenzi et al.
J Am Coll Cardiol 2004;44:1780-1785.
ABSTRACT
| FULL TEXT
Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis
Ix et al.
Nephrol Dial Transplant 2004;19:2747-2753.
ABSTRACT
| FULL TEXT
Frequently Asked Questions: Iodinated Contrast Agents
Bettmann
RadioGraphics 2004;24:S3-S10.
ABSTRACT
| FULL TEXT
Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate
Shavit et al.
JAMA 2004;292:1428-1428.
FULL TEXT
|
